| Item type |
学術雑誌論文 / Journal Article(1) |
| 公開日 |
2025-02-28 |
| タイトル |
|
|
タイトル |
Safety of alternate-day treatment with TS-1TM (tegafur/gimeracil/oteracil) in tumor-bearing dogs: a pilot study |
|
言語 |
en |
| 言語 |
|
|
言語 |
eng |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
journal article |
| 著者 |
Nishiyama, Yuta
Fukuyama, Yasuhiro
Maruo, Takuya
Yoda, Shinichiro
Iwano, Masataka
Kawarai, Shinpei
Kayanuma, Hideki
Orito, Kensuke
|
| Abstract |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
Tegafur is a prodrug of fluoropyrimidine 5-fluorouracil (5-FU), while TS-1TM is an oral fixed-dose combination of three active drugs, tegafur, gimeracil, and oteracil. This pilot study evaluated the safety of tegafur/gimeracil/oteracil in the treatment of cancers in dogs. Tegafur/gimeracil/oteracil was administered orally at a mean dose of 1.1 mg/kg twice daily on alternate days, Monday-Wednesday-Friday, every week to 11 dogs with tumors. Partial response and stable disease were observed in one dog each, whereas six exhibited progressive disease. Three dogs were not assessed. Adverse events, the most serious being grade 2, were noted in seven dogs. Adverse events were acceptable, and the drug was effective in some dogs. Therefore, tegafur/gimeracil/oteracil may be useful for treating malignant solid tumors in canines. |
|
言語 |
en |
| bibliographic_information |
The Journal of Veterinary Medical Science
巻 83,
号 8,
p. 1206-1211,
発行日 2021-06-18
|
| 出版者 |
|
|
出版者 |
The Japanese Society of Veterinary Science |
| item_10002_relation_14 |
|
|
|
識別子タイプ |
DOI |
|
|
関連識別子 |
10.1292/jvms.21-0060 |
| 出版タイプ |
|
|
出版タイプ |
VoR |
|
出版タイプResource |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| item_1730428627434 |
|
|
内容記述タイプ |
Other |
|
内容記述 |
査読あり |
83_21-0060.pdf (1.6 MB)
